



HMA-EMA Task Force on Availability of Authorised Medicines

Workshop objectives

Multi-stakeholder meeting with the HMA/EMA Task Force, London, 9 November 2018

Kristin Raudsepp
Co-Chair of HMA-EMA Task Force on Availability of authorised medicines
Director General of the Estonian State Agency of Medicines



Background – problem in the EU

- Shortages of medicinal products are a growing issue of concern in the EU and globally
- The network is increasingly confronted with supply challenges and shortages/lack of availability of both new and well-established medicines
- Unavailability of medicines in the EU, either because medicines are not marketed or because of supply disruptions, has been recognised by HMA and EMA as an area of great concern affecting all stakeholder groups.
- Problems with the availability of medicines have an impact not only on the supply chain but ultimately on healthcare systems, resulting in a significant impact on end users.
- An HMA/EMA Task Force has been set up to develop and coordinate the necessary actions to help guarantee uninterrupted supply of medicines. The Task Force is composed of three Thematic Working Groups (TWGs) tackling the problem from three critical angles: marketing authorisation, supply chain disruptions and communication.

Objectives of the workshop today

- Inform stakeholders about the HMA/EMA Task Force activities, expected deliverables including Brexit impact.
- Update stakeholders on progress with deliverables and identify areas of agreement as well as areas for further discussion.
- Share stakeholders' perspectives and (ongoing/planned) initiatives to address availability issues and discuss how these can contribute to the deliverables of the Task Force.

Any questions?

Further information

AAMTFSecretariat@ema.europa.eu

See websites for contact details

European Medicines Agency www.ema.europa.eu

Heads of Medicines Agencies www.hma.eu

Follow us on  **@EMA_News**